Doubters feel the fury of a triumphant Furiex Pharmaceuticals, as shares popped by 66% in a single day. In the following video, Motley Fool health-care analyst David Williamson explains how approval of a trio of diabetes drugs for Takeda was responsible for this pop and takes a closer look at Furiex as an investment.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.